A61K 40/4247
Proteinases
Official title: {Proteinases}
A61K40/4247 (Proteinases) appears on 34 US grants and 82 published applications in this corpus.
Search patents in A61K- Granted patents
- 34
- Published applications
- 82
- Assignees
- 54
- Inventors
- 196
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 1 | 3 |
| 2004 | 0 | 4 |
| 2005 | 2 | 0 |
| 2006 | 1 | 3 |
| 2007 | 2 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 2 | 0 |
| 2011 | 1 | 4 |
| 2012 | 1 | 0 |
| 2013 | 2 | 0 |
| 2014 | 0 | 4 |
| 2015 | 0 | 0 |
| 2016 | 2 | 2 |
| 2017 | 1 | 2 |
| 2018 | 1 | 0 |
| 2019 | 2 | 1 |
| 2020 | 1 | 2 |
| 2021 | 2 | 7 |
| 2022 | 0 | 4 |
| 2023 | 3 | 8 |
| 2024 | 6 | 14 |
| 2025 | 2 | 10 |
| 2026 | 2 | 10 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Tissue factor-targeting CAR-NK and CAR-T cell therapy19 May 2026US 12,630,605 B2Ohio State Innovation Foundation
- Methods and compositions for modulating beta chain mediated immunity9 Dec 2025US 12,492,256 B2Janssen Biotech, Inc.
- Fc-epsilon CAR7 Oct 2025US 12,435,122 B2ImmunityBio, Inc.
- Methods of isolating T cells having antigenic specificity for a cancer-specific mutation24 Dec 2024US 12,171,818 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Bi-specific adapters and their use with universal car-t cells in the treatment of tumors and the inhibition of cancer-associated fibroblasts27 Aug 2026US 2026/0248923 A1Purdue Research Foundation
- Therapeutic targeting of tumor escape by car-mediated trogocytosis20 Aug 2026US 2026/0241002 A1University of Maryland, Baltimore
- Proteins Comprising Kallikrein Related Peptidase 2 Antigen Binding Domains And Their Uses4 Jun 2026US 2026/0152559 A1Janssen Biotech, Inc.
- Fibroblast activation protein (fap) car-invariant natural killer t cells and uses thereof7 May 2026US 2026/0124303 A1Agenus Inc.
Most cited
By later US patents
- TADG-15: an extracellular serine protease overexpressed in carcinomas84US 7,291,462 B2The University of Arkansas for Medical Sciences · 2007
- Compositions and methods for targeting stromal cells for the treatment of cancer49US 9,365,641 B2The Trustees of the University of Pennsylvania · 2016
- Modified free-living microbes, vaccine compositions and methods of use thereof20US 7,833,775 B2Aduro Biotech, Inc. · 2010
- TADG-15: an extracellular serine protease overexpressed in carcinomas19US 6,649,741 B1Board of Trustees of the University of Arkansas · 2003
- Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor9US 8,546,137 B2Board of Trustees of the University of Arkansas · 2013